Avicanna's Third Quarter Report for 2025
Toronto, Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a leading biopharmaceutical company in cannabinoid-based products, has shared its financial results for Q3 2025. This quarterly report emphasizes the company's ongoing efforts to establish a stable and diversified biopharmaceutical business. The management team highlights the fruitful initiatives in medical affairs, which contribute to steady revenue growth within Canada’s medical cannabis sector.
Management Insights
Aras Azadian, the CEO of Avicanna, expressed optimism regarding the company's journey towards profitability. He stated, "Q3 reflects our commitment to building a sustainable biopharmaceutical business. Our engagement with the Canadian medical sector has propelled revenue growth, and we are translating scientific leadership into value via new intellectual property and global partnerships."
Financial Highlights from Q2 2025
Revenue Growth
In Q2 2025, Avicanna reported impressive financial figures, generating $6.40 million in revenue for the three months ending September 30, 2025, and $18.88 million for the nine-month period. Notably, Canadian revenue witnessed a 4% rise, showing a pattern of consistent growth attributed to targeted investments in medical affairs. Additionally, international revenue grew by 6% compared to the previous quarter, reinforcing the company's market presence.
Gross Profits and Margins
The gross profit for the same periods stood at $3.15 million and $9.88 million, with gross margins of 49% and 52% respectively. Although there was a decline from the prior year’s gross margin of 57%, it is important to note that this was influenced by unique costs and external factors such as the Canada Post strike. Encouragingly, the nine-month margin improved slightly from 50% due to a shift in sales dynamics.
Adjusted EBITDA Performance
Avicanna's adjusted EBITDA reflected a loss of $0.79 million for Q3, a decrease from the respective period in 2024. For the nine-month duration, the loss was $0.61 million, showing improvement compared to the previous year's loss of $0.72 million. This reduction can be linked to temporary factors impacting margins.
Corporate Developments in Q3 2025
Record Sales Achievements
The third quarter saw the company achieving record sales of 62,987 units, translating to a notable 39% increase from the same period in 2024. By the end of Q3, Avicanna had over 52 commercial SKU’s and 174 listings across various channels, marking a significant rise from prior quarters. The MyMedi.ca platform has progressively contributed to these sales, witnessing its second consecutive quarter of growth.
Innovation in Patents
Avicanna recently secured a patent from the United States Patent & Trademark Office for a topical gel intended for skincare applications. This product combines cannabinoids with other beneficial compounds to address skin conditions such as acne and wrinkles, showcasing Avicanna's commitment to innovation.
International Expansion
Remarkably, Avicanna's subsidiary completed its first export of CBD dominant cannabis flower to Switzerland, entering a significant market in Europe. This achievement extends the reach of the Aureus brand, now available in 20 international markets, bolstered by enhanced infrastructure and product portfolio diversification.
New Product Launches
In collaboration with Harrington Wellness, Avicanna launched re+PLAY, a CBD wellness brand featuring Al Harrington's innovative formulations. Initial products include topical creams and gels infused with CBD and CBG sourced from their organic hemp operations, reinforcing commitment to quality and effectiveness.
About Avicanna
Dedicated to creating evidence-based cannabinoid products, Avicanna focuses on R&D and clinical development. It has successfully commercialized over thirty unique products across multiple sectors, including medical cannabis and pharmaceuticals, demonstrating its expertise in the field.
Medical Cannabis Formulary
The RHO Phyto™ formulary provides an extensive range of cannabinoid products designed for diverse delivery methods, supporting both patients and healthcare professionals.
Pharmaceutical Pipeline and Supply Chain
Avicanna's pharmaceutical pipeline reflects its dedication to developing specialized cannabinoid candidates targeting dermatology, chronic pain, and neurological issues. Additionally, its subsidiary, Santa Marta Golden Hemp SAS, ensures a reliable supply of high-quality cannabinoids for global markets.
Frequently Asked Questions
What did Avicanna report for Q3 2025?
Avicanna reported strong revenue figures, highlighting consistent growth across Canadian markets and international expansion efforts.
What are the financial highlights for Avicanna?
The company generated $6.40 million in revenue for Q3 and noted improvements in gross profit despite some margin pressures.
How did Avicanna perform in product sales?
They achieved record sales of over 62,987 units, marking a 39% increase compared to the previous year.
What innovations did Avicanna introduce?
Avicanna received a new patent for a skincare cannabinoid product and launched the re+PLAY wellness brand.
What is the focus of Avicanna?
Avicanna focuses on the development and commercialization of cannabinoid-based products for medical and pharmaceutical uses.
